Compare STKS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKS | SGMT |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 204.2M |
| IPO Year | N/A | 2023 |
| Metric | STKS | SGMT |
|---|---|---|
| Price | $2.09 | $5.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $4.38 | ★ $27.00 |
| AVG Volume (30 Days) | 38.7K | ★ 735.0K |
| Earning Date | 03-09-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $820,588,000.00 | N/A |
| Revenue This Year | $23.94 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 51.57 | N/A |
| 52 Week Low | $1.70 | $1.73 |
| 52 Week High | $5.26 | $11.41 |
| Indicator | STKS | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 41.55 |
| Support Level | $2.23 | $5.02 |
| Resistance Level | $2.41 | $6.15 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 28.13 | 42.27 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.